Patents Examined by Fred H Reynolds
  • Patent number: 11884710
    Abstract: Peptide compounds and compositions containing the peptide compounds and methods for treating various infections, wounds, and skin conditions such as atopic dermatitis. Examples of wounds that may be treated include surface wounds such as lacerations, abrasions, avulsions, incisions, and amputations, pressure sores, bed sores, wounds due to peripheral vascular disease, post-surgical wounds, diabetic ulcers and wounds, burns, ocular wounds and abrasions, ocular ulcers, and treatment of inflammatory conditions such as dry eye. The peptide compounds and compositions may be used as treatments to enhance acceptance of grafts such as skin grafts and organ grafts.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: January 30, 2024
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Heloise Anne Pereira, Anne Kasus-Jacobi, Gina L. Griffith
  • Patent number: 11840581
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: December 12, 2023
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis, David Liu
  • Patent number: 11826464
    Abstract: Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and/or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and/or degraded within the GI tract.
    Type: Grant
    Filed: September 1, 2022
    Date of Patent: November 28, 2023
    Assignee: Rani Therapeutics, LLC
    Inventors: Mir Imran, Sara Ansaloni, Radhika Korupolu, Joel M. Harris, Mir Hashim
  • Patent number: 11820800
    Abstract: Disclosed herein are designed heterodimer proteins, monomeric polypeptides capable of forming heterodimer proteins, protein scaffolds including such polypeptides, and methods for using the heterodimer proteins and subunit polypeptides for designing logic gates.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: November 21, 2023
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: Zibo Chen, Scott Boyken, Sherry Bermeo, Robert A. Langan, David Baker
  • Patent number: 11795202
    Abstract: The invention is in the field of medicine. More specifically, it is in the field of diagnosing tumor angiogenesis status and in the field of medical treatment of a subject who is suffering, suspected to suffer, or might suffer from a tumor in the future. In particular, the invention relates to a fusion polypeptide comprising a foreign antigen and a self antigen, wherein said foreign antigen consists of a polypeptide comprising an amino acid sequence of at least 12-15 amino acid residues, 12-24% of which residues are hydrophilic, bulky amino acid residues selected from the group consisting of histidine, glutamate, arginine, glutamine, aspartic acid and/or lysine.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: October 24, 2023
    Assignee: STICHTING VUMC
    Inventors: Arjan Willem Griffioen, Elisabeth Johanna Maria Huijbers, Patrycja Nowak-Sliwinska
  • Patent number: 11780893
    Abstract: The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: October 10, 2023
    Assignee: Zealand Pharma A/S
    Inventors: Henrik Fischer Munch, Rasmus Bugge Jensen, Jens Kvist Madsen
  • Patent number: 11773136
    Abstract: Disclosed are various crystalline salt forms of Boc-D-Arg-DMT-Lys(Boc)-Phe-NH2.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: October 3, 2023
    Assignee: Stealth BioTherapeutics Inc.
    Inventor: Scott M. Duncan
  • Patent number: 11766480
    Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptoid oligomers are prepared as modulators of androgen receptor (AR), and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with unwanted or aberrant AR activity. The present peptoid oligomers are particularly valuable for the treatment of subjects with cancer.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: September 26, 2023
    Assignee: NEW YORK UNIVERSITY
    Inventors: Kent Kirshenbaum, Paul Michael Levine, Michael John Garabedian, Justin M. Holub
  • Patent number: 11746141
    Abstract: The present invention relates to a modified collagen obtainable by providing isolated collagen; freezing the isolated collagen; dehydrating the frozen collagen; and maturing the dehydrated collagen. Also disclosed are methods of preparing the modified collagen and uses thereof.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: September 5, 2023
    Assignee: INNOCOLL PHARMACEUTICALS LIMITED
    Inventors: Alexandra Dietrich, Michael Myers
  • Patent number: 11739162
    Abstract: The current invention pertains compositions and methods to generate compositions providing stability to biomolecules, including providing physiologically stable and functional DNA origami-based drug/gene delivery carriers by surface coating with the oligo-ethylene glycol conjugated peptoids of Formulas (I), (II), and (III).
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: August 29, 2023
    Assignees: Brookhaven Science Associates LLC, The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of California, The Trustees of Columbia University in the City of New York
    Inventors: Shih-Ting Wang, Oleg Gang, Ronald N. Zuckermann, Carolyn R. Bertozzi
  • Patent number: 11680088
    Abstract: The disclosure concerns snake-derived peptides and the useful application of such peptides to inhibit bacterial, fungal, viral and parasitic infections. The disclosed peptides are also useful for the treatment of an inflammatory condition or cancers.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: June 20, 2023
    Assignees: Universiteit Leiden, Academisch Ziekenhuis Leiden h.o.d.n. LUMC
    Inventors: Harald Martijn Ijsbrand Kerkkamp, Michael Keith Richardson, Gilles Philippus van Wezel, Jan Wouter Drijfhout, Robert Alexander Cordfunke, Michella Manon Voet, Petrus Hendricus Nibbering
  • Patent number: 11680091
    Abstract: The current application describes various compositions and methods for the production of FN3-based binding proteins with improved stability properties. Aspects of the disclosure relate to polypeptides comprising a variant fibronectin type III (FN3) domain from Sulfolobus tokodaii or Pyrococcus horikoshii comprising one or more amino acid substitutions or insertions in a loop region of FN3, in a non-loop region of FN3, or in both.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: June 20, 2023
    Assignee: The University of Chicago
    Inventors: Shohei Koide, Shun-Ichi Tanaka, Akiko Koide
  • Patent number: 11673929
    Abstract: The purpose of the present invention is to provide a method for producing a very stable, cyclized mutant protein such that high cyclization efficiency is achieved while the number of amino acids added is minimal and the biological properties of an original protein are maintained. In view of conformational information about the original protein, secondary structure-free regions at N/C terminal portions are deleted. Then, a protein database is screened for proteins with secondary structures similar to those of N/C terminal residues of a secondary structure-forming portion after the deletion. The screening results are used to determine the amino acid length of a loop structure through which the N-terminus and the C-terminus of the secondary structure-forming portion of the original protein are to be connected. A cyclized mutant protein is finally produced having a loop structure with the determined amino acid length.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: June 13, 2023
    Assignee: National Institute of Advanced Industrial Science and Technology
    Inventors: Shinya Honda, Takamitsu Miyafusa
  • Patent number: 11673914
    Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to ?5?1-Integrin, ?v?3-Integrin and ?v?5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: June 13, 2023
    Assignee: Allegro Pharmaceuticals, LLC
    Inventors: Michael John Mackel, John Y. Park, Hampar L. Karageozian, Vicken H. Karageozian
  • Patent number: 11666636
    Abstract: The present disclosure relates to glucagon-like peptide-1 receptor (GLP-1R) agonists and methods of treating or preventing allergic inflammation and/or methods of treating or preventing respiratory syncytial virus (RSV) infection.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: June 6, 2023
    Assignee: Vanderbilt University
    Inventors: Kevin Niswender, Stokes Peebles
  • Patent number: 11654178
    Abstract: Provided herein are cyclic prosaposin peptides and compositions and uses thereof. Exemplary uses include use in the treatment of cancer or in the treatment of inflammatory diseases or disorders.
    Type: Grant
    Filed: November 3, 2021
    Date of Patent: May 23, 2023
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventor: Randolph S. Watnick
  • Patent number: 11628133
    Abstract: The present invention relates to the cosmetic use of a composition including, as the active agent, 0.1 to 1 ?M of a synthetic peptide of sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 or one of the salts thereof in a physiologically suitable medium, in order to reduce or delay the appearance of cell senescence and signs of skin aging. The present invention also relates to a method for cosmetic treatment which relates to these novel uses, including comprising the steps of applying the composition, topically, at least once per day, for a period of at least two days.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: April 18, 2023
    Assignee: ISP Investments LLC
    Inventors: Nouha Domloge, Catherine Gondran, Ludivine Mur
  • Patent number: 11629168
    Abstract: The invention aims to provide an immunoglobulin-binding protein having improved chemical stability, especially stability against alkali. The object can be achieved by improving stability against alkali by substituting an amino acid residue(s) at a particular position(s) in an immunoglobulin-binding domain such as domain C of protein A derived from a bacterium belonging to the genus Staphylococcus, to another/other particular amino acid residue(s).
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: April 18, 2023
    Assignee: TOSOH CORPORATION
    Inventors: Naoki Yamanaka, Yukie Uchida, Yosuke Terao
  • Patent number: 11602556
    Abstract: Methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that induces conversion of naive T cells into Foxp3+ regulatory T cells to induce immunosuppression in the subject. Methods for detecting in a subject an autoimmune disease or a predisposition to a autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease, particularly type 1 diabetes.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: March 14, 2023
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Aaron Michels, Peter A. Gottlieb
  • Patent number: 11591366
    Abstract: The present invention provides a macrocyclic compound of formula (I) compositions and kits comprising this compound and their use for preventing or treating pain, or inducing hypothermia or hypotension.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: February 28, 2023
    Assignee: SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C.
    Inventors: Éric Marsault, Marc Sousbie, Richard Leduc, Philippe Sarret, Jean-Michel Longpré, Élie Besserer-Offroy, Rebecca Brouillette, Michael Desgagné